BCD-057 is a monoclonal antibodydeveloped as a biosimilar to Humira® (United States Adopted Names: adalimumab).

A monoclonal antibody is a protein engineered by scientists in the laboratory, equivalent to the natural antibodies of the immune system, aimed at binding to a specific target site in the human body¹.

BCD-057 at a concentration of 100 mg/mL is one of BIOCAD’s finished products under clinical development.

1. Weiner LM, Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–27.

This section of the website includes information about a non-authorized investigational drug product for human use.